Company intelligence / Profile preview

LisenID

Wilmington, Delaware, United States

Ownership: Private
Development stage: Other

Overview

LisenID’s QCIGISH platform has shown best-in-class sensitivity (approaching or at 99–100%) and high specificity (90%+) in the early diagnosis of cancers such as lung and thyroid, and has been validated in over 8,500 clinical cases and published in top-tier journals[1][2][3][5][6].

Therapeutic areas: Oncology
Modalities: Diagnostic platform (epigenetic imprinting technology)
Industry: Molecular Diagnostics

Partnerships

Mayo Clinic (collaboration on early cancer diagnostic solutions using QCIGISH platform)[1][3][7]

Beyond the preview

Go deeper on LisenID.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LisenID.

Explore the full profile